Early discovery candidate selection

This talk introduces early discovery candidate selection using it as a basis for further exploration of screening cascades to narrow down initial hits, to lead candidates, drug likeness criteria to identify compounds with favorable safety and bioavailability profiles and strategies to assess potency and selectivity. We will also discuss the integration of early admit characteristics, computational and experimental decision support tools and methods for prioritizing candidate portfolios. The aim is to show how systematic selection at this stage maximizes the chances of downstream drug development success. Early discovery candidate selection is a vital phase bridging the gap between initial hits and qualified leads on the path to development candidates. Selecting the right early candidates maximizes downstream success. Early selection reduces thousands of chemical or biological hits to a few high quality candidates by balancing innovation, feasibility and risk. In this session, we'll explore screening cascades, drug likeness filters, strategies for potency and selectivity, integration of AdMT characteristics, decision support tools, and the challenge of portfolio prioritization. Screening cascades are decision making frameworks guiding the triage of initial hits into lead series. The process starts with a primary screen, often high throughput, target based, or phenotypic that finds promising compounds. These undergo confirmation and